{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:41:32Z","timestamp":1778575292215,"version":"3.51.4"},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Elderly patients constitute a significant proportion of patients with psoriasis. Nonetheless, treatment for older patients is more challenging than that for younger ones. Biologic agents are preferable to other systemic drugs for elderly patients with moderate\u2010to\u2010severe psoriasis owing to their high efficacy and favorable tolerability. However, there are limited data on tuberculosis infection risk in elderly patients with psoriasis receiving biologic therapy. This study aimed to evaluate the risk of active tuberculosis and latent tuberculosis infection, assess the serial interferon\u2010gamma release assay results, and evaluate treatment compliance and adverse effects of latent tuberculosis infection treatment in elderly patients with psoriasis on biologic therapy. In this single\u2010center retrospective study, medical charts of elderly patients (age\u2009\u2265\u200965\u2009years) with psoriasis who were treated with a biologic agent (guselkumab, adalimumab, secukinumab, or ustekinumab) between January 2015 and December 2020 were reviewed. We analyzed the results of chest X\u2010rays and those of whole\u2010blood interferon\u2010gamma release assays performed for latent tuberculosis infection screening at baseline (IGRA0) and subsequently at follow\u2010up after initiating biologic therapy (IGRA1). In total, 90 patients underwent IGRA0; 46 (51.11%) of them had latent tuberculosis infection before starting biologic therapy. Overall, four and two patients experienced seroconversion and active tuberculosis during biologic therapy, respectively. The interferon\u2010gamma release assay reversion rate was 29.1%, and the interferon\u2010gamma level significantly decreased in all patients after latent tuberculosis infection treatment (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.004). Latent tuberculosis infection treatment was well tolerated in elderly patients (completion rate, 100%). The risk of latent tuberculosis infection in elderly patients with psoriasis on biologic therapy was comparable to that previously reported for all age groups. However, the active tuberculosis rate was relatively higher.<\/jats:p>","DOI":"10.1111\/1346-8138.16471","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T05:30:35Z","timestamp":1653629435000},"page":"887-894","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Risk of tuberculosis infection and serial changes in <scp>interferon\u2010gamma<\/scp> release assays in elderly patients with psoriasis receiving biologic therapy"],"prefix":"10.1111","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-9387","authenticated-orcid":false,"given":"Taehan","family":"Koo","sequence":"first","affiliation":[{"name":"Department of Dermatology Veterans Health Service Medical Center  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-1111","authenticated-orcid":false,"given":"Gayun","family":"Baek","sequence":"additional","affiliation":[{"name":"Department of Dermatology Veterans Health Service Medical Center  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8253-6188","authenticated-orcid":false,"given":"Mihn\u2010Sook","family":"Jue","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hanyang University Hospital  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14336"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13853"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12688"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12653"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200219110-00003"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419897578"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-012-0265-2"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2049-6"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14699"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2016.79.4.201"},{"key":"e_1_2_8_13_1","first-page":"170","article-title":"The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB)","volume":"11","author":"Zellweger JP","year":"2020","journal-title":"Med Lav"},{"key":"e_1_2_8_14_1","first-page":"207","article-title":"Screening for latent tuberculosis in the patient with moderate to severe psoriasis who is a candidate for systemic and\/or biologic therapy","volume":"107","author":"Martinez\u2010Lopez A","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"e_1_2_8_15_1","first-page":"159","volume-title":"Korean guidelines for tuberculosis","year":"2020"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2014.76.6.261"},{"key":"e_1_2_8_17_1","first-page":"1374","article-title":"Age\u2010related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review","volume":"14","author":"Kunst H","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.09.004"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.05.009"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00432-y"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184178"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15156"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2016.1151857"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15217"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14504"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20930116"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16866"},{"key":"e_1_2_8_29_1","first-page":"2546161","article-title":"Short\u2010term efficacy and safety of IL\u201017, IL\u201012\/23, and IL\u201023 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab and risankizumab for the treatment of moderate to severe plaque psoriasis: a systemic review and network meta\u2010analysis of randomized controlled trials","volume":"2019","author":"Bai F","year":"2019","journal-title":"J Immunol Res"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1356498"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18461"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-013-0020-3"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3343\/kjlm.2011.31.4.271"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225112"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.16471","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:16:33Z","timestamp":1692706593000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.16471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/1346-8138.16471"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.16471","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"assertion":[{"value":"2022-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}